Calcium Alpha-Ketoglutarate (CaAKG) is an essential Krebs cycle metabolite and obligate cofactor for Fe(II)/2-oxoglutarate-dependent dioxygenases, including TET DNA demethylases and JmjC histone demethylases. In landmark mouse studies, CaAKG extended female lifespan by 16.6%, compressed morbidity by 46%, and reversed epigenetic age by an average of 8.0 years in an open-label human clinical trial (TruAge clock).
Calcium AKG (Alpha-Ketoglutarate)
Calcium Alpha-Ketoglutarate (CaAKG) is an essential Krebs cycle metabolite and obligate cofactor for Fe(II)/2-oxoglutarate-dependent dioxygenases, including TET DNA demethylases and JmjC histone demethylases. In landmark mouse studies, CaAKG extended female lifespan by 16.6%, compressed morbidity by 46%, and reversed epigenetic age by an average of 8.0 years in an open-label human clinical trial (TruAge clock).
Calcium Alpha-Ketoglutarate (CaAKG) is an essential Krebs cycle metabolite and obligate cofactor for Fe(II)/2-oxoglutarate-dependent dioxygenases, including TET DNA demethylases and JmjC histone demethylases. In landmark mouse studies, CaAKG extended female lifespan by 16.6%, compressed morbidity by 46%, and reversed epigenetic age by an average of 8.0 years in an open-label human clinical trial (TruAge clock).
Will open-label human epigenetic clock reversals be validated in large, randomized, double-blind, placebo-controlled human trials?
Alpha-Ketoglutarate Extends Lifespan and Compresses Morbidity in Aging Mice
“CaAKG extended female mouse median lifespan by 16.6%, improved survivorship, reduced frailty scores by 46%, and significantly suppressed circulating systemic inflammaging cytokines (IL-6, IL-1beta).”
Reversal of biological age with alpha-ketoglutarate-based formulation: an open-label human trial
“Open-label trial design lacks blinding; potential participant lifestyle Hawthorne effect.”
Scientific Dual-Coverage Profile
Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.
Heart & Cardiovascular
Synergistic Target (30-64)Cofactor for collagen prolyl and lysyl hydroxylases, maintaining physiological arterial matrix elasticity and blunting adventitial fibrosis.
Brain Longevity & Cognition
Synergistic Target (30-64)Buffers excess ammonia in astrocytes and supports the synthesis of glutamate and GABA, sustaining cognitive bioenergetics.
Metabolic & Glycemic Health
Synergistic Target (30-64)Replenishes Krebs cycle intermediates via anaplerosis, sustaining cellular oxidative phosphorylation during metabolic stress.
Cancer Defense & Autophagy
Synergistic Target (30-64)Competitively displaces D-2-hydroxyglutarate (D-2-HG) at epigenetic dioxygenases, restoring normal DNA demethylation and tumor suppressor expression.
Endocrine Vitality & Anabolic Tone
Neutral PathwayEndogenous metabolite with neutral direct action on gonadotropin secretion.
Systemic Inflammation Suppression
Foundational Target (65-100)Promotes metabolic reprogramming of naive T-cells toward anti-inflammatory Foxp3+ regulatory T-cells, suppressing systemic inflammaging cytokines.
Bone Density & Connective Matrix
Synergistic Target (30-64)Provides both bioavailable elemental calcium and essential cofactor for prolyl 4-hydroxylase, accelerating cross-linked triple-helical bone matrix formation.
Cellular Longevity & Epigenetics
Foundational Target (65-100)Direct cosubstrate for TET family DNA demethylases and JmjC histone demethylases, reversing age-associated DNA hypermethylation and inhibiting ATP synthase to downregulate mTOR.
Functional Outcomes & Performance Impact
Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.
Physical Vitality
Clinical Endpoint: Human DNA methylation clock analysis showed an average 8-year biological age reversal after 7 months of calcium-AKG supplementation.
Skin Quality
Clinical Endpoint: Provides mandatory cofactor for prolyl hydroxylases, accelerating pro-collagen cross-linking and dermal thickness restoration.
Overall Energy
daily wellbeingClinical Endpoint: Nature study showing AKG binds ATP synthase beta subunit, inducing moderate mitochondrial uncoupling that increases metabolic energy efficiency.
Bone Matrix Health
Clinical Endpoint: Maintained trabecular bone mineral density and normalized urinary deoxypyridinoline cross-link resorption markers.
Score Breakdown: 90 / 100
Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.
Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).
Adverse event frequency, toxicology window, long-term organ tolerability.
Multi-system pleiotropy across the 8 canonical longevity vectors.
Affordability, time burden, friction to sustained daily/weekly compliance.
Practicality, Cost & Adherence Index
Calcium AKG (Alpha-Ketoglutarate) Multi-Trial Scientific Evidence
Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.
Reversal of biological age with a-ketoglutarate: an open-label human trial
Calcium AKG (Alpha-Ketoglutarate) Evidence Timeline
Initial Mechanistic Validation
Early molecular characterization demonstrates direct modulation of cellular stress pathways.
Controlled Human Pilot Trial
Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.
Calcium AKG (Alpha-Ketoglutarate) Safety Matrix
Absolute Contraindications (Do Not Use)
- •Severe hypercalcemia or hyperparathyroidism (for calcium-chelated formulations)
Pharmacological & Supplement Interactions
Theoretical calcium loading caution; monitor blood pressure.
Proven Adverse Effects vs. Theoretical Risks
- •Mild GI intolerance at very high doses (>3g)
- •Calcium over-accumulation if combined with high-dose calcium supplements
Under-Researched Populations (Evidence Gaps)
Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:
- Individuals with chronic kidney disease (CKD stage 3b-5)
Biological Relationship Graph
Combines safely with baseline longevity routines.
No direct clinical antagonisms detected.